Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations

Optimizing antipsychotic pharmacotherapy is often challenging due to significant variability in effectiveness and tolerability. Genetic factors influencing pharmacokinetics and pharmacodynamics may contribute to some of this variability. Research studies have characterized these pharmacogenetic relationships, and some genetic markers are now available as clinical tests. These advances in pharmacogenetics research and test availability have great potential to improve clinical outcomes and quality of life in psychiatric patients. For clinicians considering using pharmacogenetics, it is important to understand the clinical implications and also the limitations of markers included in currently available tests. This review focuses on pharmacokinetic and pharmacodynamic gene variants that are currently available in commercial genetic testing panels. Associations of these variants with clinical efficacy and adverse effects, as well as other clinical implications, in antipsychotic pharmacotherapy are discussed.

Download Full-text

Substance Use and Quality of Life in Young Adult Psychiatric Patients

10.26226/morressier.5885d71ad462b8028d892d0d ◽

2017 ◽

Author(s):

Joana Silva Ribeiro

Keyword(s):

Quality Of Life ◽

Substance Use ◽

Young Adult ◽

Psychiatric Patients

Download Full-text

Factors influencing health-related quality of life (HRQOL) in patients with implantable cardioverter defibrillator (ICD)

The JBI Database of Systematic Reviews and Implementation Reports ◽

10.11124/01938924-201008341-00019 ◽

2010 ◽

Vol 8 (Supplement) ◽

pp. 1-13

Author(s):

Florence Wong ◽

Sek Ying Chair

Keyword(s):

Quality Of Life ◽

Implantable Cardioverter Defibrillator ◽

Health Related Quality ◽

Cardioverter Defibrillator ◽

Factors Influencing ◽

Related Quality ◽

Health Related

Download Full-text

S32.02 Quality of life and new antipsychotic medications in schizophrenia

European Psychiatry ◽

10.1016/s0924-9338(00)94208-1 ◽

2000 ◽

Vol 15 (S2) ◽

pp. 278s-278s

Author(s):

A.G. Awad

Keyword(s):

Quality Of Life ◽

Antipsychotic Medications

Download Full-text

Analysis of Medication Adherence and Its Influencing Factors in Patients with Schizophrenia in the Chinese Institutional Environment

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18094746 ◽

2021 ◽

Vol 18 (9) ◽

pp. 4746

Author(s):

Wei Yu ◽

Jie Tong ◽

Xirong Sun ◽

Fazhan Chen ◽

Jie Zhang ◽

...

Keyword(s):

Quality Of Life ◽

Medication Adherence ◽

Activities Of Daily Living ◽

Influencing Factors ◽

Self Efficacy ◽

Daily Living ◽

Institutional Environment ◽

Factors Influencing ◽

Quality Of Life Scale

Background: Factors related to medication adherence in patients with schizophrenia have always been key to the treatment and rehabilitation of these patients. However, the treatment modes in different countries are not the same, and there is no research on the factors influencing medication adherence under different mental health service modes. Objectives: The purpose of this study was to explore medication adherence and its influencing factors in patients with schizophrenia in the Chinese institutional environment. Methods: We conducted a cross-sectional study of hospitalized persons living with schizophrenia from November 2018 to January 2019. A systematic sampling method was used to select 217 hospitalized persons living with schizophrenia. The Medication Adherence Rating Scale (MARS), Positive and Negative Syndrome Scale (PANSS), General Self-Efficacy Scale (GSES), Schizophrenia Quality of Life Scale (SQLS), and Scale of Social Skills for Psychiatric Inpatients (SSPI) were used to explore medication compliance and its influencing factors in the Chinese institutional environment. Results: The descriptive analysis and ANOVA showed that there were no significant differences in medication adherence when assessed by demographic characteristics such as sex, marital status, and education level (p > 0.05). A correlation analysis showed that there was no significant correlation between medication adherence and mental symptoms (p > 0.05) but that there was a positive correlation with self-efficacy, quality of life, and activities of daily living (p < 0.01). The linear regression analysis showed that self-efficacy, psychosocial factors, symptoms/side effects, and activities of daily living had significant effects on medication adherence (F = 30.210, p < 0.001). Conclusions: Our findings show that the self-efficacy, quality of life, and social function of patients with schizophrenia are important self-factors influencing medication adherence in the Chinese institutional environment.

Download Full-text

Path analysis for key factors influencing long-term quality of life of patients following a percutaneous coronary intervention

Coronary Artery Disease ◽

10.1097/mca.0000000000000712 ◽

2019 ◽

Vol 30 (5) ◽

pp. 339-345

Author(s):

Ling Li ◽

Hui Wang ◽

Yini Wang ◽

Xueqin Gao ◽

Guojie Liu ◽

...

Keyword(s):

Quality Of Life ◽

Percutaneous Coronary Intervention ◽

Path Analysis ◽

Coronary Intervention ◽

Key Factors ◽

Factors Influencing ◽

Percutaneous Coronary

Download Full-text

The Scandinavian Solutions for Wellness Study - an Observational Study on the Effectiveness of the Lifestyle Program Solutions for Wellness

European Psychiatry ◽

10.1016/s0924-9338(09)71191-5 ◽

2009 ◽

Vol 24 (S1) ◽

pp. 1-1

Author(s):

V. Porsdal ◽

O.K. Kleivenes ◽

C. Beal ◽

P. Svanborg

Keyword(s):

Quality Of Life ◽

Waist Circumference ◽

Observational Study ◽

Psychiatric Patients ◽

Control Group ◽

Life Styles ◽

Lifestyle Program ◽

Life Style Changes ◽

Treatment Data

Aims:It is known that psychiatric disorders often lead to unhealthy life styles and reduced quality of life, which can lead to weight gain, possibly enhanced by psychotropic treatment.Solutions for Wellness (SfW) is an educational program for life style changes for psychiatric patients. This observational study evaluated the effectiveness of SfW.Method:30 psychiatric clinics collected data for the study. Quality of life was measured by the Subjective Wellbeing under Neuroleptics scale (SWN), at baseline and at the end of SfW participation at 3 months. Demographic, disease and treatment data were also collected. A control group consisted of patients from centers that did not offer the SfW program.Results:314 patients were enrolled in SfW group, 59 in the control group. 54% of the total group had schizophrenia, 67% received atypical antipsychotics. The baseline mean BMI in the SfW group was 31.7 kg/m2.SWN scores for the SfW group improved significantly from baseline to the end of the program (mean increase 3.3 ± 12.2), but not significantly more than for the control group (mean difference 1.4, p = 0.4158 (t-test)). The SfW group demonstrated a significant decrease in BMI, weight and waist circumference from baseline. The decreases were significantly larger compared to the control group for BMI (p = 0.0018) and weight (p = 0.0027) (t-tests).Conclusion:Patients in the SfW program improved in BMI, weight, waist circumference and SWN total score. Changes in weight and BMI were significantly larger in the SfW group compared to the control group.

Download Full-text